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Purpose: To determine the phenotypic and biochemical characteristics of the p.E139K missense variant in tissue inhibitor
of metalloproteinase 3 (TIMP3) associated with Sorsby fundus dystrophy (SFD).
Methods: The coding regions and adjacent intronic sequence of TIMP3 were amplified by polymerase chain reaction and
then analyzed by bidirectional sequencing. Allele-specific PCR was used to determine the minimum allele frequency of
the mutant allele in ethnically matched controls. Clinical examination and imaging of affected individuals with color
fundus photography, scanning laser ophthalmoscope (fundal autofluorescence), and optical coherence tomography was
performed. A mutant construct of the TIMP3 protein was created and expressed in human retinal pigment epithelium
(ARPE19) cells, which were then assayed for oligomerization and intrinsic matrix metalloproteinase (MMP) inhibitory
activity.
Results: Three affected individuals from a family of Welsh origin each harbored one allele of the TIMP3 missense variant
c.415 G>A, (p.E139K), which was not identified in 534 ethnically matched control chromosomes and thus presumed
pathogenic. The mutant protein was shown to dimerize in culture cells and retain its MMP inhibitory activity. Retinal
examination was variable between eyes of affected individuals and between family members. Drusen-like deposits were
common to all three affected individuals and yellow subretinal deposits, exudative maculopathy, and geographic atrophy
were also observed. Optical coherence tomography (OCT) images of affected individuals demonstrated hyperreflectivity
of the RPE-photoreceptor-choroid complex.
Conclusions: The TIMP3 p.E139K mutation is another cause of SFD. It is the second TIMP3 sequence variant reported
that does not affect the number of cysteine residues in the mutant protein yet dimerizes in vitro. The clinical presentation
of this family is in keeping with previous clinical reports of this disorder.
Sorsby fundus dystrophy (SFD; OMIM 136900), first
described by Sorsby in 1949 [1] is a fully penetrant autosomal
dominant degenerative disease that leads to bilateral loss of
central vision due to subretinal neovascularization as well as
pigment epithelial atrophy at the macula. The course of vision
loss is often rapid and further loss of peripheral vision and
nyctalopia may also be a feature [1-4]
Age of onset ranges from the second to the eighth decade
with the majority of cases presenting during the third to fifth
decades of life [5]. Clinical findings include exudative or
atrophic lesions of the macula, drusen-like deposits at the level
of  Bruch's  membrane,  angioid  streaks,  and  plaque-like
deposits of yellow subretinal material. Prolongation of dark-
adaptation may also be present [6,7].
SFD is caused by mutations in the tissue inhibitor of
metalloproteinase  3  (TIMP3)  gene  [8],  which  encodes  a
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protein  that  is  constitutively  secreted  by  retinal  pigment
epithelium (RPE) and incorporated into Bruch’s membrane
[9,10].  Bruch’s  membrane  is  a  multilayered  extracellular
matrix  (ECM)  separating  the  RPE  from  the  vascular
choriocapillaris. Histopathological studies in donor eyes of
SFD  patients  have  revealed  that  the  abnormal  subretinal
deposits observed clinically do correspond to deposition of
protein and lipid staining material within Bruch’s membrane
[4],  which  in  SFD  donor  eyes  stains  strongly  for  TIMP3
protein [10].
The TIMP3 gene is a member of a family of four genes
that  encode  endogenous  inhibitors  of  matrix
metalloproteinases  (MMPs),  a  group  of  zinc-dependent
endopeptidases. The balance between proteolytic MMPs and
TIMPs is integral to ECM remodeling [11]. The TIMP family
members can be separated structurally and functionally into
N-terminal and C-terminal domains, each containing three
intramolecular  disulphide  bonds,  linking  12  conserved
cysteine residues within the molecule [12,13]. The N-terminal
domains of the TIMP family are more conserved in structure
and function and are required for metalloproteinase inhibition
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1218and the induction of apoptosis [14,15], while the C-terminal
domains  are  involved  in  ECM  binding  and  impart  more
individual characteristics to the TIMP family members [16].
The  C-terminal  domain  of  TIMP3  is  also  the  site  of  all
reported mutations resulting in SFD to date [6,8,17-24].
Eleven distinct mutations have been reported to cause
SFD, nine of which result in the creation [6,8,17-20], or loss
of a cysteine residue by truncation of the protein [25], or
skipping of exon 5 of the gene due to a splice site mutation
[21]. The exact nature of the initiating pathology in SFD
remains unclear. Experimental evidence suggests that in most
cases, mutant TIMP3 constructs are associated to the ECM,
retain their MMP inhibitory activity, and form high molecular
weight  protein–protein  aggregates  thought  to  result  from
additional  intermolecular  disulphide  bonds  between  the
unpaired cysteine residues created [16,26-30]. This has led
others to propose that it is the increased deposition of TIMP-3
in  Bruch’s  membrane,  rather  than  the  dysregulation  of
metalloproteinase inhibition, that is likely to be the primary
initiating event in SFD [31].
However, not all studies of TIMP3 mutants support these
findings. One report, for example, found the p.S156C- TIMP3
mutant  retained  its  MMP  inhibitory  activity  and  lacked
dimerization [32].
Moreover, two SFD-linked mutations, p.H158R [22] and
p.E139K [23,24], the focus of this study, failed to generate an
unpaired cysteine residue in the predicted mutant protein. This
may  indicate  a  disease  mechanism  independent  from
disulphide-mediated oligomerization.
METHODS
Patient selection and clinical evaluation: A three-generation
British family of Welsh origin with an autosomal dominant
history of retinal degeneration was referred to the Medical
Retina clinic at Moorfields Eye Hospital (Figure 1). Three
affected and two unaffected family members were available
for study. The protocol of the study adhered to the provisions
of  the  Declaration  of  Helsinki  and  was  approved  by  the
Moorfields Eye Hospital Ethics Committee. Genomic DNA
was isolated from whole blood using an extraction kit (GE
Healthcare Ltd, Buckinghamshire, UK). For the three affected
individuals, full medical histories were taken and ophthalmic
examination undertaken, including LogMAR visual acuities,
slit-lamp biomicroscopy, color fundus photography, optical
coherence tomography using 6-mm-length scans centered on
the fovea (Stratus optical coherence tomography-OCT; Carl
Zeiss  Meditec,  Dublin,  CA),  and  fundus  autofluorescence
imaging,  performed  with  a  confocal  scanning  laser
ophthalmoscope (cSLO, HRA, Heidelberg, Germany).
Images of fundus autofluorescence were recorded with a
40° field-of-view mode through a dilated pupil. The ametropic
corrector was employed to correct for refractive error. An
argon blue laser (488 nm) was used for excitation, and the
emitted light of >495 nm was detected with a barrier filter. To
amplify the autofluorescence signal, a flash mode was used.
At least 24 single autofluorescence images of 512×512 pixels
were acquired in series mode with a frequency of 12 images
per second. The best 10 images were selected for automatic
alignment and the creation of a single mean image for each
eye.
Mutation  screening  and  sequence  analyses:  Exon  5  and
flanking intronic sequences of TIMP3 were amplified from
genomic DNA extracted from peripheral blood. Polymerase
chain reactions (PCR; 25 µl) were performed using primer
sequences described previously [8], containing the following:
200 ng genomic DNA, 12.5 µl 2X Mastermix (AB-0575,
Figure 1. Pedigree of family showing
genotypes for the c.415 G>A sequence
variant in TIMP3. Affected individuals
are shown in black. Genotypes for the c.
415 G>A sequence variant (p.E139K) in
TIMP3  are  shown  underneath.
Abbreviations:  G/G  represents
homozygous  wild  type  and  G/A
represents heterozygous for the mutant
allele.
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1219Expression  constructs  of  mutant  TIMP-3:  The  reference
coding  DNA  (cDNA)  sequence  of  wild  type  TIMP3  was
derived from NCBI database (NM_000362) and the protein
sequence from (NP_000353). As in previous reports of TIMP3
sequence changes, the initial 69 nucleotides from the cDNA
reference sequence (23 amino acids from the wild type protein
sequence) were omitted from numbering; these nucleotides
form a signal peptide for TIMP3 and do not form part of the
functional molecule.
Wild-type pCDNA3 TIMP3 was used as the template and
the forward primer 5′-TTG TGA CTT CCA AGA ACA AGT
GTC TCT GGA CCG AC-3′, the reverse primer 5′-GTC GGT
CCA GAG ACA CTT GTT CTT GGA AGT CAC AA-3′. The
new construct, named pDNA3 E139K TIMP3, was confirmed
by sequence analysis. The mutant construct was transfected
in to ARPE-19 cells and incubated at 37 °C with 5% CO2 for
24 h. The medium was then changed into the selection medium
containing Blasticidin S HCl at 5 μg/ml (Invitrogen, Carlsbad,
CA). The cells were subcultured for 4 passages in 12 days in
a T75 tissue culture flask. The ECM was harvested and protein
sample was prepared. Nonreduced sample was separated on
15%  polyacrylamide  gels  containing  0.09%  SDS  and
transferred onto Polyvinylidene fluoride (PVDF) membrane.
The membrane was incubated in blocking buffer (TBS, 0.1%
Tween-20, 5% skimmed milk) for 12 h at 4 °C then probed
with  primary  antibody  (Sigma-Aldrich,  St.  Louis,  MO;
T7687) diluted 1:3,000 in blocking buffer for 16 h at 4 °C.
The membrane was then probed with secondary goat anti-
rabbit-HRP (P0448) antibody diluted 1:10,000 in blocking
buffer at room temperature. The membrane was washed in
TBS, 0.1% Tween-20 for 10 min following each antibody
incubation. This process was performed three times. Protein
was detected using ECL Advance Western Blotting Detection
Kit  (GE  Healthcare  UK  Ltd,  Little  Chalfont,
Buckinghamshire,  UK)  according  to  the  manufacturer’s
instructions.
Determining allele frequency in a control population: The
prevalence of the p.E139K allele in a control population was
assessed  using  a  validated  competitive  allele-specific
polymerase chain reaction. The control population consisted
of  188  unrelated  UK  blood  donors  from  the  European
Collection of Cell Cultures (ECCAC, Salisbury, UK) and 79
unrelated volunteers from the Institute of Ophthalmology,
London, UK.
Assay  of  MMP  inhibitory  activity  in  the  E139K  mutant:
Protease/substrate  SDS–PAGE  (reverse  zymography)  of
mutant protein was performed to ascertain inhibitory activity
of the TIMP3 containing fractions identified. Gelatin retained
in SDS–PAGE gel was used as an in situ proteinase substrate.
The  proteolytic  activity  was  reversibly  inhibited  by  SDS
during electrophoresis and renatured in subsequent washes by
exchange of SDS with a nonionic detergent (Triton X-100,
Sigma-Aldrich). Gel was then incubated with MMP-2 as well
as  MMP-9  (gelatinase)  for  3–4  h.  Partial  degradation  of
gelatin  was  seen  apart  from  in  those  regions  containing
fractions of TIMP3 with preserved MMP inhibitory function.
The gels were then stained with Coomassie blue; the dark blue
bands locating TIMP activity were visualized against the pale
blue background of partially degraded gelatin [25].
RESULTS
Identification of a disease-causing sequence variant in exon
5 of TIMP3: The sequence variant c.415 G>A, resulting in a
glutamate  to  lysine  substitution  p.E139K  (Figure  2)  was
identified in all three symptomatic members of the family.
This change was found to segregate with the disease (Figure
1).
Allele frequency in control population: The sequence variant
c.415 G>A, resulting in a glutamate to lysine substitution
p.E139K (Figure 2) was identified in all three symptomatic
members of the family. This change was found to segregate
with the disease (Figure 1) and was not found in 534 ethnically
matched control chromosomes.
Clinical assessment: The index father (II:4) in the pedigree
was  deceased  at  the  time  of  investigation.  He  reportedly
suffered with progressive reduction in night vision starting in
his third decade, with subsequent bilateral loss of central and
peripheral vision by his fourth decade. The index mother (II:
3) reported no ophthalmic history other than senile cataract
and was not found to harbor the mutant allele. The clinical
findings  for  affected  individuals  in  this  pedigree  are
summarized in Table 1.
The  three  affected  subjects  carrying  the  p.E139K
mutation all reported progressive reduction in night vision and
slow dark adaptation during their fifth decade (mean age of
onset  of  nyctalopia=45.7  years;  standard  error  of  the
mean=2.4 years). In each case these symptoms predated the
onset of sudden vision loss in the first eye from between 1 to
11 years.
No anterior segment abnormalities or visually significant
lens  opacity  were  noted  in  any  of  the  three  affected
individuals, and no history of renal or systemic disease was
Molecular Vision 2009; 15:1218-1230 <http://www.molvis.org/molvis/v15/a130> © 2009 Molecular Vision
1220
Abgene, Thermo Fisher Scientific, Leicestershire, UK), 3 µl
of 2 mM forward and 3 µl of 2 mM reverse primer and 3.5 µl
dH2O. Amplified PCR products were purified enzymatically
using 1 µl ExoSAP-IT (GE Healthcare Ltd.) added to 5 µl of
PCR  product  and  20  µl  of  dH2O.  These  samples  were
incubated at 37 °C for 15 min and heat inactivated at 80 °C
for  15  min.  Purified  PCR  product  was  then  sequenced
bidirectionally with 1 µl forward or reverse primer (2 µM
stock), 1 µl BigDye (version 3.1) terminator cycle sequencing
chemistry and 5 µl buffer (Applied Biosystems, Warrington,
UK) as per the manufacturer’s protocol. The product was
analyzed  on  an  ABI  3100  Genetic  Analyzer  (Applied
Biosystems, Applera, UK). The sequence was examined for
alterations with Lasergene DNA Star software (DNA Star
Inc., Madison, WI).found to segregate with the disorder in this pedigree. Yellow
drusen-like  deposits  were  present  in  all  eyes  of  the  three
affected individuals to varying amounts but most obvious in
III:1 (see Figure 3).
Hemorrhagic choroidal neovascularization (CNV) was
the initial cause of sudden central vision loss in all three cases.
At the time of examination the two older affected siblings had
bilateral central vision loss (III:1 and III:3). The youngest (III:
4) had unilateral vision loss, with his left eye showing no signs
of CNV and maintaining good visual acuity.
At the time of last examination, retinal appearance varied
greatly  between  family  members,  with  individual  III:1
displaying  an  atrophic  maculopathy,  individual  III:2
displaying  intraretinal  fluid  and  pigment  epithelial
detachment. Individual III:4 had a striking fundal appearance
in  his  affected  eye,  demonstrating  widespread  floccular
yellow subretinal deposits, a large retinal pigment epithelial
tear and evidence of extrafoveal neovascularization (Figure
3).
OCT3 images from affected eyes displayed areas of RPE
detachment and intraretinal cystic spaces (IRC), consistent
with  the  choroidal  neovascularization  observed  clinically
(Figure 4, Figure 5, and Figure 6). An additional finding in
both eyes of III:1 and III:4 was increased reflectivity at the
level of the RPE-choroid complex. The left eye of III:4 did
not have any evidence of CNV or vision loss, but the OCT
scan showed evidence of retinal atrophy, in particular the loss
of the outer nuclear layer temporal to the fovea (see Figure
6B).
Fundal  autofluorescence  imaging  showed  areas  of
irregular hyper and hypofluorescence in all eyes with vision
loss.  In  the  eye  without  vision  loss  (III:4),  fundal
autofluoresence did not reveal any significant abnormality
(Figure 7).
Expression construct and assay of MMP inhibitory activity of
the p.E139K mutant: Western blotting of the ECM extracts
revealed a monomeric TIMP3 form in addition to a dimeric
form at circa 48 kDa (Figure 8). The inhibitory activity of
p.E139K  TIMP3  mutant  protein  was  tested  by  reverse
zymography, using recombinant MMP-2 as an in-gel MMP
activity. The dimerized TIMP3 p.E139K mutant could be seen
as a high band with the size of 48 kDa in the gel with the
presence of p.E139K TIMP3 monomer in the size of 24 kDa.
Results of reverse zymography demonstrated that p.E139K
TIMP3 mutant retained its MMP inhibitory activity and also
could form a dimer within the ECM (Figure 9).
Assay of MMP inhibitory activity in the p.E139K mutant: The
inhibitory activity of p.E139K TIMP3 mutant protein was
tested by reverse zymography, using recombinant MMP-2 as
an  in-gel  MMP  activity.  The  dimerized  TIMP3  p.E139K
mutant could be seen as a high band with the size of 48 kDa
in the gel with the presence of p.E139K TIMP3 monomer in
the  size  of  24  kDa.  Results  of  reverse  zymography
demonstrated that p.E139K TIMP3 mutant retained its MMP
Figure  2.  Electropherogram  from
affected  family  member  III:4.
Representative electropherogram from
the  sense  strand  of  genomic  DNA
showing  (A)  heterozygous  G>A
missense  change,  (B)  wild  type
sequence. The wild-type codon frame
and amino acid number (139) is also
shown.
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e
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t
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nFigure 3. Color fundus photographs of the three affected individuals. All three affected individuals demonstrated the presence of yellow drusen-
like deposits bilaterally throughout their fundi, but to varying amounts. A: Individual III:1 had bilateral geographic atrophy and widespread
subretinal drusen-like deposits throughout the posterior pole extending beyond the vascular arcades. B: Individual III:3 had subretinal and
intraretinal fluid at the macula in the right eye extending inferiorly toward the temporal arcades. In the right eye, two extrafoveal foci of
subretinal hemorrhage were also noted, inferior to the optic disc and temporal to the macula. In the left eye (poorest visual acuity), subretinal
fluid and a pigment epithelial detachment were noted superior to the macula. Although not visible on this image, areas of chorioretinal atrophy
were also noted nasal to the disc. C: Individual III:4 had a large subretinal fibrovascular scar visible in the right eye. Foci of subretinal
hemorrhage, exudates, and secondary retinal detachment are also visible. Areas of floccular yellowish subretinal deposit can be seen throughout
the fundus in the right eye. In the left eye (without visual loss) only small yellowish subretinal deposits can be seen throughout the posterior
pole.
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1223Figure 4. OCT3 scans (6 mm) centered on the fovea. (A) from a normal adult individual. Landmarks such as outer nuclear layer (ONL), inner
and outer photoreceptor segment junction (IS), retinal pigment epithelium (RPE), and choriocapillaris (CC) are indicated. (B) from affected
individual III:1 Right eye (OD) C: Individual III:1 Left eye (OS). Both B and C demonstrate hyperreflective signals (*) at the level of the
RPE-choroid complex. The foveal pit appears steep in the right eye (OD). Parafoveal intraretinal cysts (IRC) are demonstrated bilaterally.
There is also evidence of parafoveal retinal atrophy in the left eye (OS).
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1224Figure 5. OCT3 scans (6 mm) centered on the fovea. From the right eye (A) and left eye (B and C) of affected individual III:3. The right eye
(OD) demonstrates inframacular retinal thickening due to intraretinal cystic changes (IRC). The left eye (OS) demonstrates central retinal
thinning and both retinal and pigment epithelial detachment (RPED) superior to the fovea. In the left eye there is hypereflectivity at the level
of the choroid nasal to the fovea.
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1225inhibitory activity and also could form a dimer within the
ECM (Figure 9).
DISCUSSION
The  Welsh  pedigree  reported  herein  had  clinical  findings
consistent  with  a  diagnosis  of  SFD.  Affected  members
segregated  the  c.415  G>A  missense  change  in  TIMP3,
resulting in a glutamic acid to a lysine change at amino acid
position 139 (p.E139K). This sequence variant was not found
in 534 control chromosomes and thus was thus considered
highly likely to cause the retinal disease in this family. This
change  has  also  been  reported  independently  in  a  Swiss
pedigree with SFD [24].
Ocular  features  in  other  pedigrees  with  SFD  show
interfamilial and intrafamilial variation, the reasons for this
being unclear. The majority of SFD-causing mutations give
rise  to  an  unpaired  cysteine  residue  and  onset  of  disease
between the third and fourth decade of life. There appears to
Figure 6. OCT3 scans (6 mm) centered on the fovea. From the right eye (A) and left eye (B) of affected individual III:4. Hyperreflectivity (*)
at the level of the RPE-choroid complex is noted throughout the macula in the right eye (OD) and to a lesser extent in the left eye (OS). The
right eye also demonstrates intraretinal cysts throughout the macula and a large central retinal detachment. The left eye demonstrates flattening
of the foveal pit and loss of the outer nuclear layer temporal to the fovea.
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1226Figure 7. Fundus autofluorescence images of three affected individuals. A (right eye) and B (left eye) of individual III:1. Showing bilateral
discrete areas of central confluent hypofluorescence associated with the areas of geographic atrophy noted clinically. The borders of this area
are hyperfluorescent. C (right eye) D (left eye) of individual III:3. Bilateral areas of stippled hyperfluorescence and hypofluorescence extending
toward the vascular arcades corresponding to the areas of subretinal fluid noted clinically. E (right eye) F (left eye) of individual III:4. In the
right eye, a large stippled area of hyperfluorescence and hypofluorescence extending beyond the vascular arcades was noted. Of note, the
areas of floccular yellow deposits seen on funduscopy were hypofluorescent on fundus autofluorescence imaging. Fundal autofluorescence
in the left eye (without visual loss) was unremarkable.
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1227be some relationship between mutation and age of vision loss,
with  some  TIMP3  mutations,  such  as  p.S156C  [17]  and
p.G166C [18,33], giving rise to vision loss as early as the
second decade. Vision loss as late as the sixth to eighth decade
has been reported in two Japanese pedigrees, segregating a
splice site change [21]. Due to the lack of a proven theory
explaining the biochemical mechanisms resulting in SFD,
others have suggested that such phenotypic differences may
relate to other genetic disease modifiers in affected pedigrees
rather than the differences in mutations themselves [31].
The p.E139K reported here is the second reported TIMP3
mutation  causing  SFD  that  fails  to  generate  an  unpaired
Figure  8.  Western  Blot  of  E139K
TIMP-3  mutant.  TIMP3  immunoblot
(western blot) of the extracellular matrix
sample from ARPE-19 cells transfected
with  E139K  TIMP-3  expression
plasmid,  in  nonreduced  form
demonstrating dimerization.
Figure  9.  Reverse  zymogram  of
extracellular  matrix  from  the  E139K
TIMP3  mutant.  The  left  lane
demonstrates  that  the  matrix
metalloproteinase  (MMP)  inhibitory
activity  of  the  standard  purified  wild
type  TIMP3  is  retained  in  both  its
glycosylated  and  nonglycosylated
forms.  Middle  lane  demonstrates  that
the TIMP3 E139K mutant also retains
MMP  inhibitory  activity.  Right  lane
represents  the  expression  plasmid  of
E139K TIMP-3 with a polyhistidine tag,
the  addition  of  which  resulted  in
increased  molecular  weight  compared
to the untagged construct in the middle
lane.
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1228cysteine  residue,  the  other  being  p.H158R  [22].  Of  note,
affected  individuals  from  pedigrees  harboring  both  these
missense changes develop vision loss later in life (fifth to sixth
decade) than in most other reported cases of SFD [22]. The
reasons for this are unclear.
The propensity for mutant TIMP3 to form dimers has
been explained by the presence of unpaired cysteine residues
in these mutant molecules leading to aberrant intermolecular
disulphide bonds [16,26-30]. Despite having an even number
of cysteine residues, the p.E139K mutant protein expressed in
ARPE-19 cells, forms dimers on western blotting and retains
its MMP inhibitory activity. The change in charge at amino
acid position 139, resulting from the positively charged lysine
substituting the negatively charged glutamic acid may explain
the  dimerization  of  the  p.E139K  mutant  observed.  This
change in charge may result in a disruption of disulphide bond
formation at adjacent amino acid position 140. Further work
would be required to test this hypothesis. Another hypothesis
to explain the observed dimerization of the p.E139K mutant,
could be the steric hindrance of the adjacent cysteine residue
at amino acid position 140 by the substitution of lysine for a
glutamate; however this is probably unlikely as both residues
are of similar size.
An interesting finding in the OCT scans from the pedigree
reported here was the abnormal hyperreflectivity noted at the
RPE-choroid interface. A previous report of serial OCT scans
in one individual with SFD showed a focal thickening of the
RPE band at the location of subsequent CNV development
[34].  Examination  of  SFD  donor  eyes  have  documented
abnormal sub-RPE deposit and thickened Bruch’s membrane
[4,35].  It  is  tempting  to  suggest  that  the  sub-RPE
hyperreflectivity demonstrated by this pedigree may represent
the thickened Bruch’s membrane observed in donor eyes.
However  this  hyperreflectivity  may  simply  represent  an
artifact resulting from the increased light penetration due to
overlying RPE atrophy or subretinal fibrosis from end stage
CNV. Interestingly the OCT scan of the left eye (without
central  vision  loss)  from  individual  III:4  showed
hyperreflectivity at the RPE-choroid interface but did not
show any evidence of RPE disturbance on autofluorescence
imaging  (Figure  7E,F).  This  suggests  that  the
hyperreflectivity may originate from below the RPE, perhaps
from Bruch’s membrane.
Another interesting feature in the same OCT scan from
the only eye without central vision loss was the retinal atrophy
—specifically, loss of the outer nuclear layer in the perifoveal
region. It is possible that atrophy of this rod-rich region of the
retina may represent the early morphological changes related
to the symptoms of nightblindness reported by this individual
four years earlier.
In summary, we have described the detailed phenotype
of an SFD family with a disease causing TIMP3 mutation. The
glutamic acid at position 139 in the TIMP3 molecule has
previously shown to be mutated to a nonsense codon and is
thus the first residue in the TIMP3 protein to cause SFD by
two  different  classes  of  mutation.  It  is  also  the  second
sequence variant reported in this disorder that does not affect
the number of cysteine residues in the predicted sequence of
the TIMP3 protein, yet still exhibits dimerization in vitro. The
mutant protein also retains its function as an MMP inhibitor.
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